177 related articles for article (PubMed ID: 37783786)
1. UBE3B promotes breast cancer progression by antagonizing HIF-2α degradation.
Wang Y; Liu X; Wang M; Wang Y; Wang S; Jin L; Liu M; Zhou J; Chen Y
Oncogene; 2023 Nov; 42(46):3394-3406. PubMed ID: 37783786
[TBL] [Abstract][Full Text] [Related]
2. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
[TBL] [Abstract][Full Text] [Related]
3. Inactivation of VHL by tumorigenic mutations that disrupt dynamic coupling of the pVHL.hypoxia-inducible transcription factor-1alpha complex.
Miller F; Kentsis A; Osman R; Pan ZQ
J Biol Chem; 2005 Mar; 280(9):7985-96. PubMed ID: 15611064
[TBL] [Abstract][Full Text] [Related]
4. Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway.
Carroll VA; Ashcroft M
Cancer Res; 2006 Jun; 66(12):6264-70. PubMed ID: 16778202
[TBL] [Abstract][Full Text] [Related]
5. Emetine promotes von Hippel-Lindau-independent degradation of hypoxia-inducible factor-2α in clear cell renal carcinoma.
Kong HS; Lee S; Beebe K; Scroggins B; Gupta G; Lee MJ; Jung YJ; Trepel J; Neckers L
Mol Pharmacol; 2010 Dec; 78(6):1072-8. PubMed ID: 20813864
[TBL] [Abstract][Full Text] [Related]
6. The relationship of erythropoietin overexpression with von Hippel-Lindau tumour suppressor gene mutations between hypoxia-inducible factor-1α and -2α in sporadic clear cell renal carcinoma.
Gong K; Zhang N; Zhang K; Na Y
Int J Mol Med; 2010 Dec; 26(6):907-12. PubMed ID: 21042786
[TBL] [Abstract][Full Text] [Related]
7. Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3'-kinase/Akt signaling pathway.
Blancher C; Moore JW; Robertson N; Harris AL
Cancer Res; 2001 Oct; 61(19):7349-55. PubMed ID: 11585776
[TBL] [Abstract][Full Text] [Related]
8. Hsp70 and CHIP selectively mediate ubiquitination and degradation of hypoxia-inducible factor (HIF)-1alpha but Not HIF-2alpha.
Luo W; Zhong J; Chang R; Hu H; Pandey A; Semenza GL
J Biol Chem; 2010 Feb; 285(6):3651-3663. PubMed ID: 19940151
[TBL] [Abstract][Full Text] [Related]
9. Hypoxia-inducible factor-2α stabilizes the von Hippel-Lindau (VHL) disease suppressor, Myb-related protein 2.
Okumura F; Joo-Okumura A; Nakatsukasa K; Kamura T
PLoS One; 2017; 12(4):e0175593. PubMed ID: 28394947
[TBL] [Abstract][Full Text] [Related]
10. pVHL-mediated degradation of HIF-2α regulates estrogen receptor α expression in normoxic breast cancer cells.
Higashimura Y; Kitakaze T; Harada N; Inui H; Nakano Y; Yamaji R
FEBS Lett; 2016 Aug; 590(16):2690-9. PubMed ID: 27323688
[TBL] [Abstract][Full Text] [Related]
11. Parkin targets HIF-1α for ubiquitination and degradation to inhibit breast tumor progression.
Liu J; Zhang C; Zhao Y; Yue X; Wu H; Huang S; Chen J; Tomsky K; Xie H; Khella CA; Gatza ML; Xia D; Gao J; White E; Haffty BG; Hu W; Feng Z
Nat Commun; 2017 Nov; 8(1):1823. PubMed ID: 29180628
[TBL] [Abstract][Full Text] [Related]
12. RNF4 and VHL regulate the proteasomal degradation of SUMO-conjugated Hypoxia-Inducible Factor-2alpha.
van Hagen M; Overmeer RM; Abolvardi SS; Vertegaal AC
Nucleic Acids Res; 2010 Apr; 38(6):1922-31. PubMed ID: 20026589
[TBL] [Abstract][Full Text] [Related]
13. Beluga whale pVHL enhances HIF-2α activity via inducing HIF-2α proteasomal degradation under hypoxia.
Bi J; Hu B; Wang J; Liu X; Zheng J; Wang D; Xiao W
Oncotarget; 2017 Jun; 8(26):42272-42287. PubMed ID: 28178687
[TBL] [Abstract][Full Text] [Related]
14. HIF-1alpha and EPAS ubiquitination mediated by the VHL tumour suppressor involves flexibility in the ubiquitination mechanism, similar to other RING E3 ligases.
Paltoglou S; Roberts BJ
Oncogene; 2007 Jan; 26(4):604-9. PubMed ID: 16862177
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic regulation of HIF-1α in renal cancer cells involves HIF-1α/2α binding to a reverse hypoxia-response element.
Xu J; Wang B; Xu Y; Sun L; Tian W; Shukla D; Barod R; Grillari J; Grillari-Voglauer R; Maxwell PH; Esteban MA
Oncogene; 2012 Feb; 31(8):1065-72. PubMed ID: 21841824
[TBL] [Abstract][Full Text] [Related]
16. Fibrosis and hypoxia-inducible factor-1α-dependent tumors of the soft tissue on loss of von Hippel-Lindau in mesenchymal progenitors.
Mangiavini L; Merceron C; Araldi E; Khatri R; Gerard-O'Riley R; Wilson TL; Sandusky G; Abadie J; Lyons KM; Giaccia AJ; Schipani E
Am J Pathol; 2015 Nov; 185(11):3090-101. PubMed ID: 26348575
[TBL] [Abstract][Full Text] [Related]
17. Cobalt inhibits the interaction between hypoxia-inducible factor-alpha and von Hippel-Lindau protein by direct binding to hypoxia-inducible factor-alpha.
Yuan Y; Hilliard G; Ferguson T; Millhorn DE
J Biol Chem; 2003 May; 278(18):15911-6. PubMed ID: 12606543
[TBL] [Abstract][Full Text] [Related]
18. Expression of hypoxia-inducible factor 1alpha, hypoxia-inducible factor 2alpha, and von Hippel-Lindau protein in epithelial ovarian neoplasms and allelic loss of von Hippel-Lindau gene: nuclear expression of hypoxia-inducible factor 1alpha is an independent prognostic factor in ovarian carcinoma.
Osada R; Horiuchi A; Kikuchi N; Yoshida J; Hayashi A; Ota M; Katsuyama Y; Melillo G; Konishi I
Hum Pathol; 2007 Sep; 38(9):1310-20. PubMed ID: 17555795
[TBL] [Abstract][Full Text] [Related]
19. Regulation of HIF prolyl hydroxylases by hypoxia-inducible factors.
Aprelikova O; Chandramouli GV; Wood M; Vasselli JR; Riss J; Maranchie JK; Linehan WM; Barrett JC
J Cell Biochem; 2004 Jun; 92(3):491-501. PubMed ID: 15156561
[TBL] [Abstract][Full Text] [Related]
20. Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2-driven VHL-/- renal cancer.
Smith K; Gunaratnam L; Morley M; Franovic A; Mekhail K; Lee S
Cancer Res; 2005 Jun; 65(12):5221-30. PubMed ID: 15958567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
